Buy Laurus Labs; target of Rs 340 : Motilal Oswal
Motilal Oswal is bullish on Laurus Labs recommended buy rating on the stock with a target price of Rs 340 in its research report dated April 27, 2023.28-04-2023
28-04-2023
Laurus Labs Ltd - 540222 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyLaurus Labs Ltd 2CIN NO.L24239AP2005PLC047518 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 552.37 4Highest Credit Rating during the previous FY AA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CARE RATINGS LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. YES Name of the Company Secretary: G VENKATESWAR REDDY Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER EmailId: secretarial@lauruslabs.com Name of the Chief Financial Officer: V V RAVI KUMAR Designation: EXECUTIVE DIRECTOR AND CHIEF FINANCIAL OFFICER EmailId: secretarial@lauruslabs.com Date: 28/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.28-04-2023
Laurus Labs Results Earnings Call for Q4FY23
Conference Call with Laurus Labs Management and Analysts on Q4FY23 Performance and Outlook. Listen to the full earnings transcript.27-04-2023
Laurus Labs Ltd - 540222 - Related Party Transactions For The Half Year Ended March 31, 2023
Related party transactions for the half year ended March 31, 202327-04-2023
Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 & 46 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and with reference to our Results conference call intimation dated April 21, 2023, please be informed that the Results conference call for Full year and Q4 FY23 was hosted on April 27, 2023 and the web link for the audio recording of the conference call is as follows: https://www.lauruslabs.com/Investors/PDF/Q4/ANT0420230427146368.mp3 Please take the information on record.27-04-2023
Q4FY23 Quarterly & FY23 Annual Result Announced for Laurus Labs Ltd.
Pharmaceuticals company Laurus Labs announced Q4FY23 & FY23 results: Q4FY23: Revenue at Rs 1,381 crore, decreased by 3% (YoY) EBITDA at Rs 287 crore, decreased by 28% (YoY) EBITDA margins at 20.8% PAT at Rs 103 crore, decreased by 55% (YoY) PAT margins at 7.5% EPS (Diluted) for the period at Rs 1.9 per share (not annualised) Interim Dividend of Rs 1.2/- per share. FY23: Revenue at Rs 6,041 crore, increased 22% (YoY) EBITDA at Rs 1,594 crore, increased by 11% (YoY) EBITDA margins at 26.4% PAT at Rs 790 crore, decreased by 4% (YoY) PAT margins at 13.1% EPS (Diluted) (face value of Rs 2/-) at Rs 14.6 per share Commenting on the highlights, Founder and Chief Executive Officer Dr. Satyanarayana Chava stated, "FY23 has been a year of significant achievement and meaningful progress despite a challenging macro environment. We delivered strong full-year results driven by robust underlying business performance in our key growth pillars CDMO, and Non-ARVs generic portfolio. Our R&D-driven; commercial strategy continued to make advancements at speed and we are making efficient use of strongly linked technology platform and manufacturing excellence to seize new business opportunities, and widening our target market. Our investment programs are well on track with a focus on long-term success. We are also continuing to drive forward our sustainability agenda. We are entering FY24 with greater confidence that we’re creating a sustainable engine that will bring forth greater business resilience and generate long-term sustainable value for stakeholders well into next decade." Commenting on the results, V V Ravi Kumar, Executive Director & Chief Financial Officer said, “We delivered good financial performance for FY23 in line with our revised outlook. We achieved Rs 6,041 crore in revenues, representing 22% revenues growth, and Rs 1,594 crore EBITDA, equating to 26.4% margin. Business mix had positively contributed to margins but the negative operating leverage on new capacities commissioned, higher inflation and Fx impact let to the overall margin fall compared to last year. We are working on several initiatives around efficiency improvement, which should partly mitigate its impact in FY24. Our future capex projects towards strengthening CDMO and Non-ARV generics are advancing as per schedule and Debt leverage position remains comfortable. Our Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D; Projects. We achieved, Rs 1,381 crore in revenues, representing 3% revenues decline, and Rs 287 crore EBITDA, resulting in 20.8% margin." Result PDF27-04-2023
Laurus Labs Ltd - 540222 - Book Closure For AGM
Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, this is to inform you that the Register of Members and Share Transfer Books of the Company will remain closed from July 08, 2023 to July 14, 2023 (both days inclusive) for the purpose of 18th Annual General Meeting. The next Annual General Meeting of the Company shall be held on Friday, July 14, 2023 at 3.00 pm through Video Conferencing or Other Audio-Visual Means (OVAM) as per the Circulars issued by the Ministry of Corporate Affairs and Securities and Exchange Board of India.27-04-2023
Laurus Labs Ltd - 540222 - Corporate Action-Board approves Dividend
The Board of Directors of the Company in their meeting held on April 27, 2023 have approved for the payment of 02nd interim dividend of Rs. 1.20/- (60%) per equity share of Rs.2/- each, for the Financial Year 2022-23. Further, pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, the Company has fixed 'May 10, 2023' as 'Record Date' for determining the eligibility of the Shareholders. The Dividend amount will be paid on or after May 18, 2023. The Board Meeting commenced at 02.00 PM and concluded at 02.45 PM.27-04-2023
Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release for Q4 FY 202327-04-2023
Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor PPT dated APRIL 27, 202327-04-2023